Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The greatest growth among GLP-1 receptor agonists in prescriptions for patients with type 1 diabetes occurred with semaglutide (Ozempic/Rybelsus/Wegovy, Novo Nordisk), which rose from 0.2% in 2018 to 4.4% in 2023, whereas tirzepatide (Mounjaro/Zepbound, Eli Lilly) was prescribed in 1.3% of patients with type 1 diabetes in 2023 after being introduced in 2022
Table 3 Health state, event, drug acquisition and consumable costs used in the analysis, expressed in 2025 Euros ()
Pick the drug based on the evidence that applies to you, then build the protocol around it
PMID: 22338093
Both drugs offer impressive results for weight loss and metabolic health benefits, but their high cost often makes access a challenge
Follow-up is just as important as baseline review
US$ 24.60
US$ 29.12
US$ 27.60
US$ 28.75
US$ 21.00
